At a glance
ClinicalIndex Comparison Record- ✓Biopsy-proven Kaposi sarcoma involving skin with or without visceral involvement
- ✓Treatment-naïve, refractory, intolerant, or previously systemically treated (including liposomal doxorubicin)
- ✓ECOG performance status ≤2 or Karnofsky ≥60%
- ✓Life expectancy >3 months
- ✕Anti-neoplastic treatment for KS (chemotherapy, radiotherapy, local treatment including topical 5-FU, biological or investigational therapy) within 4 weeks (or 6 weeks for nitrosoureas/mitomycin C) prior to enrollment, OR non-recovery from prior adverse events
- ✕Brain metastases
- ✕Symptomatic visceral or pulmonary KS, or symptomatic KS impairing functional status (front-line cytotoxic therapy indicated)
- ✕Concurrent neoplasia requiring cytotoxic therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacological Study, and 2 other interventions for Skin Kaposi Sarcoma. Completed, enrolled 23 participants across 9 sites.
Signals
Detailed Summary
This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.
Study Details
Timeline
Arms & Interventions
Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
Interventions
Correlative studies
Correlative studies
Ancillary studies
Given IV